Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT04348136
PHASE2/PHASE3

An Extension Study of JR-141 in Patients With Mucopolysaccharidosis Type II

Sponsor: JCR Pharmaceuticals Co., Ltd.

View on ClinicalTrials.gov

Summary

Multicenter, open-label, single-group, designed to evaluate the long term efficacy and safety of study drug for the treatment of the MPS II.

Key Details

Gender

MALE

Age Range

Any - Any

Study Type

INTERVENTIONAL

Enrollment

27

Start Date

2019-09-01

Completion Date

2030-03-31

Last Updated

2025-07-24

Healthy Volunteers

No

Interventions

DRUG

JR-141

IV infusion, 2.0 mg/kg/week

Locations (20)

Fukui Clinical site

Fukui, Japan

Fukuoka Clinical site 2

Fukuoka, Japan

Fukuoka Clinical site

Fukuoka, Japan

Gifu Clinical site

Gifu, Japan

Hiroshima Prefectural Hospital

Hiroshima, Japan

Hokkaido Clinical site

Hokkaido, Japan

Kananagawa Ckinical site

Kanagawa, Japan

Kumamoto Clinical site

Kumamoto, Japan

Okayama Clinical site

Okayama, Japan

Okayama Clinical site 2

Okayama, Japan

Okinawa Clinical site

Okinawa, Japan

Osaka Clinical site 3

Osaka, Japan

Osaka Clinical site 2

Osaka, Japan

Osaka Clinical site

Osaka, Japan

Saitama Clinical site

Saitama, Japan

Shizuoka Clinical site

Shizuoka, Japan

Shizuoka Clinical site 2

Shizuoka, Japan

Tochigi Clinical site

Tochigi, Japan

Tokyo Clinical site

Tokyo, Japan

Tottori Clinical site

Tottori, Japan